Literature DB >> 18827260

New and old players in the hepcidin pathway.

Clara Camaschella, Laura Silvestri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18827260     DOI： 10.3324/haematol.13724

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

Review 1.  Anaemia in inflammatory rheumatic diseases.

Authors:  Günter Weiss; Georg Schett
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

2.  Iron-deficiency anemia from matriptase-2 inactivation is dependent on the presence of functional Bmp6.

Authors:  Anne Lenoir; Jean-Christophe Deschemin; Léon Kautz; Andrew J Ramsay; Marie-Paule Roth; Carlos Lopez-Otin; Sophie Vaulont; Gaël Nicolas
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

3.  Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation.

Authors:  Andrea U Steinbicker; Chetana Sachidanandan; Ashley J Vonner; Rushdia Z Yusuf; Donna Y Deng; Carol S Lai; Kristen M Rauwerdink; Julia C Winn; Borja Saez; Colleen M Cook; Brian A Szekely; Cindy N Roy; Jasbir S Seehra; Gregory D Cuny; David T Scadden; Randall T Peterson; Kenneth D Bloch; Paul B Yu
Journal:  Blood       Date:  2011-03-10       Impact factor: 22.113

Review 4.  Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis.

Authors:  Andrew J Ramsay; John D Hooper; Alicia R Folgueras; Gloria Velasco; Carlos López-Otín
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

5.  Study of Serum Hepcidin as a Potential Mediator of the Disrupted Iron Metabolism in Obese Adolescents.

Authors:  Hayam K Nazif; Azza Abd El-Shaheed; Karima A I El-Shamy; Manal A Mohsen; Nevein N Fadl; Rehab S I Moustafa
Journal:  Int J Health Sci (Qassim)       Date:  2015-04

6.  Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells.

Authors:  Gustav Holmgren; Jane Synnergren; Yalda Bogestål; Caroline Améen; Karolina Åkesson; Sandra Holmgren; Anders Lindahl; Peter Sartipy
Journal:  Toxicology       Date:  2014-12-18       Impact factor: 4.221

7.  Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.

Authors:  Carlo A Gaillard; Andreas H Bock; Fernando Carrera; Kai-Uwe Eckardt; David B Van Wyck; Sukhvinder S Bansal; Maureen Cronin; Yvonne Meier; Sylvain Larroque; Simon D Roger; Iain C Macdougall
Journal:  PLoS One       Date:  2016-06-08       Impact factor: 3.240

Review 8.  Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?

Authors:  Theresa McDonagh; Iain C Macdougall
Journal:  Eur J Heart Fail       Date:  2015-01-30       Impact factor: 15.534

9.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

10.  Hepcidin and Its Role in Iron Homeostasis.

Authors:  Justyna Kwapisz; Artur Slomka; Ewa Zekanowska
Journal:  EJIFCC       Date:  2009-08-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.